| Literature DB >> 25629920 |
Abdelmoneim Ismail Awad1, Fatemah Mohammad Alsaleh1.
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM), coronary heart disease (CHD) and metabolic syndrome (MetS) are major healthcare problems in Kuwait. The present study was designed to determine the prevalence of MetS, and to estimate the 10-year risk for developing T2DM and CHD among the general population in Kuwait.Entities:
Mesh:
Year: 2015 PMID: 25629920 PMCID: PMC4309592 DOI: 10.1371/journal.pone.0116742
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
General characteristics of the study subjects.
| Characteristics | n (%, 95% CI) | Gender | Nationality | ||
|---|---|---|---|---|---|
| Male | Female | Kuwaiti | Non-Kuwaiti | ||
| n(%) | n(%) | n(%) | n(%) | ||
| n = 1610 | n = 628 | n = 982 | n = 1107 | n = 503 | |
|
| |||||
| Single | 451 (28.0, 25.8, 30.3) | 149 (23.7) | 302 (30.8) | 343 (31.0) | 108 (21.5) |
| Married | 1076 (66.8, 64.5–69.1) | 458 (72.9) | 618 (62.9) | 695 (62.8) | 381 (75.7) |
| Divorced | 59 (3.7, 2.8–4.7) | 16 (2.6) | 43 (4.4) | 48 (4.3) | 11 (2.2) |
| Widowed | 24 (1.5, 1.0–2.3) | 5 (0.8) | 19 (1.9) | 21 (1.9) | 3 (0.6) |
|
| |||||
| 20–44 | 1108 (68.8, 66.5–71.0) | 402 (64.0) | 706 (71.9) | 782 (70.6) | 326 (64.8) |
| 45–54 | 338 (21.0, 19.0–23.1) | 134 (21.3) | 204 (20.8) | 223 (20.1) | 115 (22.9) |
| 55–64 | 132 (8.2, 6.9–9.7) | 75 (11.9) | 57 (5.8) | 83 (7.5) | 49 (9.7) |
| ≥ 65 | 32 (2.0, 1.4–2.8) | 17 (2.8) | 15 (1.5) | 19 (1.7) | 13 (2.6) |
|
| |||||
| Low-intermediate education | 309 (19.2, 17.3–21.2) | 119 (18.9) | 190 (19.3) | 172 (15.5) | 137 (27.2) |
| High education | 1301 (80.8, 78.8–82.6) | 509 (81.1) | 792 (80.7) | 935 (84.5) | 366 (72.8) |
|
| |||||
| Capital | 187 (11.6, 10.1–13.3) | 62 (9.9) | 125 (12.7) | 155 (14.0) | 32 (6.4) |
| Hawalli | 348 (21.6, 19.6–23.7) | 131 (20.9) | 217 (22.1) | 216 (19.5) | 132 (26.2) |
| Al-Farwaniyah | 438 (27.2, 25.1–29.5) | 177 (28.2) | 261 (26.6) | 306 (27.6) | 132 (26.2) |
| Al-Ahmadi | 317 (19.7,17.8–21.7) | 134 (21.3) | 183 (18.6) | 206 (18.6) | 111 (22.1) |
| Al-Jahra | 200 (12.4,10.9–14.2) | 75 (11.9) | 125 (12.8) | 116 (10.5) | 84 (16.7) |
| Mubarak Al-Kabeer | 120 (7.5, 6.2–8.9) | 49 (7.8) | 71 (7.2) | 108 (9.8) | 12 (2.4) |
|
| |||||
| < 500 | 440 (27.3, 25.2–29.5) | 143 (22.7) | 297 (30.2) | 203 (18.3) | 237 (47.1) |
| 500–1000 | 586 (36.4, 34.1–38.8) | 165 (26.3) | 421 (42.9) | 410 (37.0) | 176 (35.0) |
| > 1000 | 584 (36.3, 33.9–38.6) | 320 (51.0) | 264 (26.9) | 494 (44.6) | 90 (17.9) |
|
| |||||
| Excellent | 532 (33.0, 30.8–35.4) | 218 (34.7) | 314 (32.0) | 423 (38.2) | 109 (21.7) |
| Very good | 585 (36.3, 34.0–38.7) | 211 (33.6) | 374 (38.1) | 413 (37.3) | 172 (34.2) |
| Good | 443 (27.5, 25.4–29.7) | 181 (28.8) | 262 (26.7) | 248 (22.4) | 195 (38.8) |
| Fair | 50 (3.1, 2.3–4.1) | 18 (2.9) | 32 (3.2) | 23 (2.1) | 27 (5.4) |
|
| |||||
| Yes | 314 (19.5, 17.6–21.5) | 119 (18.9) | 195 (19.9) | 223 (20.1) | 91 (18.1) |
| No | 1296 (80.5, 78.5–82.3) | 509 (81.1) | 787 (80.1) | 884 (79.9) | 412 (81.9) |
|
| |||||
| Yes | 256 (15.9, 14.2–17.8) | 229 (36.5) | 27 (2.7) | 173 (15.6) | 83 (16.5) |
| No | 1354 (84.1, 82.2–85.8) | 399 (63.5) | 955 (97.3) | 934 (84.4) | 420 (83.5) |
n: Number of participants;
#: Overall percentage;
*: Percentage within gender;
^: Percentage within nationality;
CI: Confidence interval; Yrs: years; KD: Kuwaiti Dinars
Physical and biochemical laboratory data of the study subjects.
| Physical and laboratory characteristics | n (%, 95% CI) | Gender | Nationality | ||
|---|---|---|---|---|---|
| Male | Female | Kuwaiti | Non-Kuwaiti | ||
| n(%) | n(%) | n(%) | n(%) | ||
| n = 1610 | n = 628 | n = 982 | n = 1107 | n = 503 | |
|
| |||||
| < 130 | 1115 (69.3, 66.9–71.5) | 376 (59.9) | 739 (75.2) | 789 (71.3) | 326 (64.8) |
| 130–139 | 365 (22.7, 20.7–24.8) | 170 (27.1) | 195 (19.9) | 252 (22.7) | 113 (22.5) |
| ≥ 140 | 130 (8.1, 6.8–9.5) | 82 (13.0) | 48 (4.9) | 66 (6.0) | 64 (12.7) |
|
| |||||
| < 85 | 1315 (81.7, 79.7–83.5) | 469 (74.7) | 846 (86.2) | 929 (83.9) | 386 (76.8) |
| 85–89 | 160 (9.9, 8.5–11.5) | 81 (12.9) | 79 (8.0) | 111 (10.0) | 49 (9.7) |
| ≥ 90 | 135 (8.4, 7.1–9.9) | 78 (12.4) | 57 (5.8) | 67 (6.1) | 68 (13.5) |
|
| |||||
| < 130/85 | 1043 (64.8, 62.4–67.1) | 339 (54.0) | 704 (71.7) | 741 (66.9) | 302 (60.0) |
| ≥ 130–139/85–89 | 370 (23.0, 21.0–25.1) | 171 (27.2) | 199 (20.3) | 267 (24.2) | 103 (20.5) |
| ≥ 140/90 | 197 (12.2, 10.7–13.9) | 118 (18.8) | 79 (8.0) | 99 (8.9) | 98 (19.5) |
|
| |||||
| < 4.14 | 405 (25.2, 23.1–27.3) | 154 (24.5) | 251 (25.6) | 287 (26.0) | 118 (23.4) |
| 4.14–5.16 | 649 (40.3, 37.9–42.7) | 254 (40.5) | 395 (40.2) | 451 (40.7) | 198 (39.4) |
| ≥ 5.17 | 556 (34.5, 32.2–36.9) | 220 (35.0) | 336 (34.2) | 369 (33.3) | 187 (37.2) |
|
| |||||
|
| |||||
| < 1.03 | 235 (37.4) | 140 (36.8) | 95 (38.3) | ||
| ≥ 1.03 | 393 (62.6) | 240 (63.2) | 153 (61.7) | ||
|
| |||||
| < 1.3 | 482 (49.1) | 340 (46.8) | 142 (55.7) | ||
| ≥ 1.3 | 500 (50.9) | 387 (53.2) | 113 (44.3) | ||
|
| |||||
| < 1.7 | 1188 (73.8, 71.6–75.9) | 424 (67.5) | 764 (77.8) | 837 (75.6) | 351 (69.8) |
| 1.7–2.25 | 212 (13.2, 11.6–14.9) | 101 (16.1) | 111 (11.3) | 138 (12.5) | 74 (14.7) |
| ≥ 2.26 | 210 (13.0, 11.5–14.8) | 103 (16.4) | 107 (10.9) | 132 (11.9) | 78 (15.5) |
|
| |||||
| < 5.6 | 1154 (71.7, 69.4–73.8) | 428 (68.2) | 726 (73.9) | 814 (73.5) | 340 (67.6) |
| ≥ 5.6 | 456 (28.3, 26.2–30.6) | 200 (31.8) | 256 (26.1) | 293 (26.5) | 163 (32.4) |
n: Number of participants;
#: Overall percentage;
*: Percentage within gender;
^: Percentage within nationality;
CI: Confidence interval; Kg: Kilogram; m: Meter; BP: Blood pressure; mm Hg: Millimeter mercury; TC: Total cholesterol; HDL-C: High density lipoprotein cholesterol; TG: Triglycerides; FPG: Fasting plasma glucose; mmol/L: Millimoles per liter.
Distribution of FINDRISK variables of the study subjects.
| Variable | n (%, 95% CI) | Gender | Nationality | ||
|---|---|---|---|---|---|
| Male | Female | Kuwaiti | Non-Kuwaiti | ||
| n(%) | n(%) | n(%) | n(%) | ||
| n = 1610 | n = 628 | n = 982 | n = 1107 | n = 503 | |
|
| |||||
| < 25 | 631 (39.2, 36.8–41.6) | 209 (33.3) | 422 (43.0) | 449 (40.5) | 182 (36.2) |
| 25–30 | 631 (39.2, 36.8–41.6) | 296 (47.1) | 335 (34.1) | 419 (37.9) | 212 (42.1) |
| >30 | 348 (21.6, 19.6–23.7) | 123 (19.6) | 225 (22.9) | 239 (21.6) | 109 (21.7) |
|
| |||||
|
| |||||
| < 94 | 368 (58.6) | 206 (54.5) | 162 (64.8) | ||
| 94–102 | 137 (21.8) | 89 (23.5) | 48 (19.2) | ||
| >102 | 123 (19.6) | 83 (22.0) | 40 (16.0) | ||
|
| |||||
| <80 | 342 (34.9) | 272 (37.3) | 70 (27.7) | ||
| 80–88 | 239 (24.3) | 169 (23.2) | 70 (27.7) | ||
| >88 | 401 (40.8) | 288 (39.5) | 113 (44.6) | ||
|
| |||||
| Yes | 979 (60.8, 58.4–63.2) | 416 (66.2) | 563 (57.3) | 665 (60.1) | 314 (62.4) |
| No | 631 (39.2, 36.8–41.6) | 212 (33.8) | 419 (42.7) | 442 (39.9) | 189 (37.6) |
|
| |||||
| Yes | 762 (47.3, 44.9–49.8) | 289 (46.0) | 473 (48.2) | 523 (47.2) | 239 (47.5) |
| No | 848 (52.7, 50.2–55.1) | 339 (54.0) | 509 (51.8) | 584 (52.8) | 264 (52.5) |
|
| |||||
| Yes | 187 (11.6, 10.1–13.3) | 84 (13.4) | 103 (10.5) | 118 (10.7) | 69 (13.7) |
| No | 1423 (88.4, 86.7–89.9) | 544 (86.6) | 879 (89.5) | 989 (89.3) | 434 (86.3) |
|
| |||||
| Yes | 146 (9.1, 7.7–10.6) | 47 (7.5) | 99 (10.1) | 91 (8.2) | 55 (10.9) |
| No | 1464 (90.9, 89.4–92.3) | 581 (92.5) | 883 (89.9) | 1016 (91.8) | 448 (89.1) |
|
| |||||
| Yes | 1158 (71.9, 69.7–74.1) | 427 (68.0) | 731 (74.4) | 851 (76.9) | 307 (61.0) |
| No | 452 (28.1, 25.9–30.4) | 201 (32.0) | 251 (25.6) | 256 (23.1) | 196 (39.0) |
FINDRISK: The Finnish Diabetes Risk Score; n: Number of participants;
#: Overall percentage;
*: Percentage within gender;
^: Percentage within nationality;
CI: Confidence interval; BMI: Body mass index; Kg/m2: Kilogram per square meter; cm: Centimeter.
General characteristics and variables of FINDRISK and FRS of study subjects by gender (n = 1610).
| Characteristic | Male (n = 628) | Female (n = 982) | p-value | ||
|---|---|---|---|---|---|
| Mean (SD) or Frequency (%) | Median (IQR) | Mean (SD) or Frequency (%) | Median (IQR) | ||
|
| 39.8 (12.7) | 39.0 (29.0–49.0) | 36.4 (12.1) | 35.0 (25.0–45.0) | <0.001 |
|
| 1.73 (0.08) | 1.73 (1.68–1.78) | 1.61 (0.07) | 1.60 (1.56–1.65) | <0.001 |
|
| 81.6 (16.0) | 80.0 (70.0–90.0) | 69.1 (15.1) | 67.0 (59.0–78.0) | <0.001 |
|
| 92.4 (14.9) | 91.4 (81.3–100.0) | 86.4 (16.0) | 84.0 (75.0–96.0) | <0.001 |
|
| 125 (12) | 125 (120–130) | 121 (12)1 | 120 (112–129) | <0.001 |
|
| 80 (7) | 80 (78–85) | 77 (8) | 76 (66–77) | <0.001 |
|
| 5.3 (1.0) | 5.3 (4.8–5.7) | 5.2 (0.9) | 5.1 (4.7–5.6) | 0.002 |
|
| 4.9 (1.0) | 4.8 (4.1–5.5) | 4.9 (1.0) | 4.8 (4.1–5.5) | 0.687 |
|
| 1.17 (0.31) | 1.10 (0.97–1.30) | 1.30 (0.34) | 1.30 (1.07–1.52) | <0.001 |
|
| 1.5 (0.90) | 1.3 (0.9–1.9) | 1.2 (0.7) | 1.0 (0.7–1.6) | <0.001 |
|
| 27.1 (4.6) | 26.6 (24.1–29.3) | 26.7 (5.7) | 25.8 (22.8–29.7) | 0.003 |
|
| 0.843 | ||||
| Low-intermediate education | 119 (18.9) | 190 (19.3) | |||
| High education | 509 (81.1%) | 792 (80.7) | |||
|
| 0.654 | ||||
| Yes | 119 (18.9) | 195 (19.9) | |||
| No | 509 (81.1) | 787 (80.1) | |||
|
| <0.001 | ||||
| Yes | 229 (36.5) | 27 (2.7) | |||
| No | 399 (63.5) | 955 (97.3) | |||
|
| <0.001 | ||||
| Yes | 416 (66.2) | 563 (57.3) | |||
| No | 212 (33.8) | 419 (42.7) | |||
|
| 0.400 | ||||
| Yes | 289 (46.0) | 473 (48.2) | |||
| No | 339 (54.0) | 509 (51.8) | |||
|
| 0.078 | ||||
| Yes | 84 (13.4) | 103 (10.5) | |||
| No | 544 (86.6) | 879 (89.5) | |||
|
| 0.077 | ||||
| Yes | 47 (7.5) | 99 (10.1) | |||
| No | 581 (92.5) | 883 (89.9) | |||
|
| 0.005 | ||||
| Yes | 427 (68.0) | 731 (74.4) | |||
| No | 201 (32.0) | 251 (25.6) | |||
FINDRISK: The Finnish Diabetes Risk Score; FRS: The Framingham Risk Score; n: Number of participants; CI: Confidence interval; SD: Standard deviation;
IQR: Interquartile range; Yrs: Years; m: Meter; Kg: Kilogram; cm: Centimeter; BP: Blood pressure; mm Hg: Millimeter mercury; FPG: Fasting plasma glucose;
mmol/L: Millimoles per liter; TC: Total cholesterol; HDL-C: High density lipoprotein cholesterol; TG: Triglycerides; BMI: Body mass index; Kg/m2: Kilogram per square meter.
Association between participants who were found to have MetS and their characteristics (n = 512).
| Characteristics | OR (95% CI) | p-value | Sample Weighted OR (95% CI) | p-value |
|---|---|---|---|---|
|
| 0.494 | 0.754 | ||
| Male | Reference | Reference | ||
| Female | 0.92 (0.71–1.18) | 0.93 (0.60–1.45) | ||
|
| <0.001 | |||
| 20–44 | Reference | Reference | 0.005 | |
| 45–54 | 2.54 (1.92–3.38) | 2.34 (1.41–3.86) | ||
| 55–64 | 3.23 (2.14–4.87) | 2.46 (1.15–5.28) | ||
| ≥ 65 | 3.16 (1.44–6.95) | 2.29 (0.80–6.54) | ||
|
| 0.098 | 0.512 | ||
| Kuwaiti | 0.78 (0.58–1.05) | 0.85 (0.52–1.39) | ||
| Non-Kuwaiti | Reference | Reference | ||
|
| 0.867 | 0.878 | ||
| Low-intermediate education | 1.03 (0.75–1.41) | 0.97 (0.65–1.45) | ||
| High education | Reference | Reference | ||
|
| 0.068 | 0.154 | ||
| Capital | Reference | Reference | ||
| Hawalli | 0.92 (0.59–1.43) | 1.18 (0.54–2.54) | ||
| Al-Farwaniyah | 1.50 (0.99–2.27) | 1.43 (0.69–2.97) | ||
| Al-Ahmadi | 1.08 (0.69–1.69) | 0.72 (0.33–1.55) | ||
| Al-Jahra | 0.74 (0.45–1.22) | 0.64 (0.27–1.51) | ||
| Mubarak Al-Kabeer | 0.83 (0.46–1.48) | 0.70 (0.22–2.26) | ||
|
| 0.610 | 0.332 | ||
| < 500 | Reference | Reference | ||
| 500–1000 | 0.99 (0.71–1.36) | 1.15 (0.64–2.08) | ||
| > 1000 | 1.10 (0.77–1.57) | 0.72 (0.37–1.39) | ||
|
| <0.001 | 0.022 | ||
| Yes | Reference | Reference | ||
| No | 1.74 (1.37–2.20) | 1.67 (1.08–2.59) | ||
|
| 0.722 | 0.817 | ||
| Yes | Reference | Reference | ||
| No | 0.96 (0.76–1.21) | 0.95 (0.61–1.48) | ||
|
| <0.001 | <0.001 | ||
|
| Reference | Reference | ||
|
| 2.28 (1.71–3.04) | 1.94 (1.15–3.27) | ||
|
| 6.77 (4.92–9.33) | 4.52 (2.56–8.01) |
MetS: Metabolic syndrome: n: Number of participants; OR: Odds ratio; CI: Confidence interval; KD: Kuwaiti Dinars; Kg/m2: Kilogram per square meter.
Estimated risk of developing T2DM within 10-years in the study population per FINDRISK (n = 1610).
| Individual risk Score | Estimated probability of developing diabetes | Frequency (%, 95% CI) |
|---|---|---|
| Low risk (< 7) | 1 in 100 | 566 (35.2, 32.8–37.6) |
| Slightly elevated risk (7–11) | 1 in 25 | 563 (34.9, 32.7–37.4) |
| Moderate risk (12–14) | 1in 6 | 269 (16.7, 14.9–18.6) |
| High risk (15–20) | 1 in 3 | 195 (12.1, 10.6–13.8) |
| Very high risk (> 20) | 1 in 2 | 17 (1.1, 0.6–1.7) |
T2DM: Type 2 diabetes mellitus; FINDRISK: The Finnish Diabetes Risk Score; n: Number of participants; CI: Confidence interval
Association between participants at moderate/high/very high risk to develop T2DM and/or CHD, and their characteristics.
| Moderate/high/very high risk to develop T2DM (n = 481) | Moderate/high to develop CHD (n = 283) | Moderate/high/very high risk to develop both T2DM/CHD (n = 136) | ||||
|---|---|---|---|---|---|---|
| Characteristics | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value |
|
| <0.001 | <0.001 | 0.039 | |||
| Male | Reference | Reference | Reference | |||
| Female | 2.08 (1.58–2.75) | 0.22 (0.16–0.32) | 0.62 (0.. 39–0.98) | |||
|
| <0.001 | <0.001 | <0.001 | |||
| 20–44 | Reference | Reference | Reference | |||
| 45–54 | 2.75 (2.06–3.69) | 10.63 (7.14–15.82) | 12.76 (6.76–24.09) | |||
| 55–64 | 3.97 (2.59–6.08) | 38.78 (23.27–64.62) | 32.14 (16.08–64.23) | |||
| ≥ 65 | 10.16 (4.10–25.14) | 42.04 (17.17–94.13) | 64.03 (23.41–175.17) | |||
|
| 0.090 | 0.245 | 0.177 | |||
| Kuwaiti | 1.30 (0.96–1.75) | 1.26 (0.85–1.87) | 1.42 (0.85–2.35) | |||
| Non-Kuwaiti | Reference | Reference | Reference | |||
|
| 0.038 | 0.811 | 0.459 | |||
| Low-intermediate Education | 1.43 (1.02–2.00) | 1.05 (0.69–1.1) | 1.22 (0.72–2.06) | |||
| High education | Reference | Reference | Reference | |||
|
| 0.419 | 0.256 | 0. 766 | |||
| Capital | Reference | Reference | Reference | |||
| Hawalli | 1.50 (0.94–2.39) | 0.80 (0.52–1.24) | 0.62 (0.30–1.29) | |||
| Al-Farwaniyah | 1.16 (0.74–1.83) | 1.16 (0.69–1.96) | 0.60 (0.29–1.25) | |||
| Al-Ahmadi | 1.37 (0.85–2.20) | 0.62 (0.32–1.23) | 0.75 (0.35–1.59) | |||
| Al-Jahra | 1.32 (0.78–2.24) | 0.49 (0.19–1.25) | 0.66 (0.29–1.54) | |||
| Mubarak Al-Kabeer | 1.64 (0.91–2.94) | 0.69 (0.36–1.32) | 0.87 (0.32–2.38) | |||
|
| 0.001 | 0.603 | 0.118 | |||
| < 500 | Reference | Reference | Reference | |||
| 500–1000 | 1.67 (1.18–2.37) | 0.79 (0.49–1.27) | 0.82 (0.43–1.57) | |||
| > 1000 | 2.11 (1.45–3.08) | 0.81 (0.. 49–1.34) | 1.45 (0.75–2.82) | |||
|
| <0.001 | <0.001 | <0.001 | |||
| Yes | 5.12 (3.96–6.61) | 2.81 (2.01–3.92) | 4.82 (3.08–7.53) | |||
| No | Reference | Reference | Reference | |||
T2DM: Type 2 diabetes mellitus; CHD: Coronary heart disease; n: Number of participants; OR: Odds ratio; CI: Confidence interval; Yrs: Years; KD: Kuwaiti Dinars;
MetS: Metabolic syndrome.
Association quantified by sample weighted regression between participants at moderate/high/very high risk to develop T2DM and/or CHD, and their characteristics.
| Moderate/high/very high risk to develop T2DM (n = 481) | Moderate/high to develop CHD (n = 283) | Moderate/high/very high risk to develop both T2DM/CHD (n = 136) | ||||
|---|---|---|---|---|---|---|
| Characteristics | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value |
|
| 0.001 | <0.001 | 0.061 | |||
| Male | Reference | Reference | Reference | |||
| Female | 2.27 (1.39–3.72) | 0.18 (0.10–0.34) | 0.48 (0.22–1.04) | |||
|
| <0.001 | <0.001 | <0.001 | |||
| 20–44 | Reference | Reference | Reference | |||
| 45–54 | 2.65 (1.56–4.50) | 6.42 (3.11–13.22) | 12.50 (3.37–46.40) | |||
| 55–64 | 3.57 (1.80–7.11) | 29.40 (11.73–73.72) | 35.44 (9.22–136.18) | |||
| ≥ 65 | 14.32 (3.81–53.80) | 30.57 (12.10–77.27) | 81.40 (16.72–396.37) | |||
|
| 0.208 | 0.210 | 0.679 | |||
| Kuwaiti | 1.40 (0.83–2.36) | 0.67 (0.35–1.26) | 0.82 (0.32–2.12) | |||
| Non-Kuwaiti | Reference | Reference | Reference | |||
|
| 0.040 | 0.084 | 0.175 | |||
| Low-intermediate Education | 1.53 (1.02–2.30) | 1.57 (0.94–2.60) | 1.62 (0.81–3.26) | |||
| High education | Reference | Reference | Reference | |||
|
| 0.066 | 0.753 | 0. 141 | |||
| Capital | Reference | Reference | Reference | |||
| Hawalli | 2.10 (0.93–4.79) | 0.59 (0.15–2.33) | 0.92 (0.27–3.13) | |||
| Al-Farwaniyah | 1.03 (0.44–2.40) | 0.42 (0.10–1.71) | 0.34 (0.09–1.27) | |||
| Al-Ahmadi | 1.92 (0.82–4.54) | 0.42 (0.10–1.67) | 0.98 (0.29–3.40) | |||
| Al-Jahra | 2.25 (0.98–5.61) | 0.61 (0.15–2.53) | 1.23 (0.35–4.34) | |||
| Mubarak Al-Kabeer | 2.32 (0.97–7.21) | 0.41 (0.07–2.41) | 2.40 (0.52–9.11) | |||
|
| 0.008 | 0.308 | 0.178 | |||
| < 500 | Reference | Reference | Reference | |||
| 500–1000 | 1.96 (1.07–3.59) | 1.37 (0.65–2.90) | 0.87 (0.31–2.41) | |||
| > 1000 | 2.76 (1.42–5.36) | 1.86 (0.84–4.08) | 2.42 (0.74–7.91) | |||
|
| <0.001 | <0.001 | <0.001 | |||
| Yes | 5.04 (3.13–8.13) | 3.46 (1.87–6.37) | 7.23 (3.41–15.32) | |||
| No | Reference | Reference | Reference | |||
T2DM: Type 2 diabetes mellitus; CHD: Coronary heart disease; n: Number of participants; OR: Odds ratio; CI: Confidence interval; Yrs: Years; KD: Kuwaiti Dinars;
MetS: Metabolic syndrome.